JP2010195731A - Dopa oxidase activity inhibitor and beautifying agent - Google Patents

Dopa oxidase activity inhibitor and beautifying agent Download PDF

Info

Publication number
JP2010195731A
JP2010195731A JP2009044191A JP2009044191A JP2010195731A JP 2010195731 A JP2010195731 A JP 2010195731A JP 2009044191 A JP2009044191 A JP 2009044191A JP 2009044191 A JP2009044191 A JP 2009044191A JP 2010195731 A JP2010195731 A JP 2010195731A
Authority
JP
Japan
Prior art keywords
extract
plant
oxidase activity
dopa oxidase
activity inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009044191A
Other languages
Japanese (ja)
Inventor
Kyoko Amano
恭子 天野
Mitsuru Sugiyama
充 杉山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp filed Critical Kao Corp
Priority to JP2009044191A priority Critical patent/JP2010195731A/en
Publication of JP2010195731A publication Critical patent/JP2010195731A/en
Withdrawn legal-status Critical Current

Links

Landscapes

  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide a dopa oxidase activity inhibitor and a beautifying agent. <P>SOLUTION: The dopa oxidase activity inhibitor and the beautifying agent comprise as an effective ingredient an extract of at least one plant selected from the group consisting of Angelica archangelica, Benthamidia florida, Euphorbia kansui Liou, Rhus chinensis Mill., Cnidium monnieri(L.) Cuss., Agrimonia pilosa Ledeb., Diuranthera minor C.H.Wright Hemsl., and Berberis aristata. <P>COPYRIGHT: (C)2010,JPO&INPIT

Description

本発明は、ドーパオキシダーゼ活性抑制剤および美白剤に関する。   The present invention relates to a dopa oxidase activity inhibitor and a whitening agent.

日焼け後の色素沈着やシミ・ソバカスは、一般に皮膚の紫外線暴露による刺激やホルモンの異常又は遺伝的要素等によって皮膚内に存在する色素細胞(メラノサイト)が活性化されメラニン産生が亢進した結果生じるものと考えられている。生体内において、色素メラニンは色素細胞(メラノサイト)内のメラノソームにおいて、前駆体であるチロシンから生合成される。このメラニン生合成に関わる酵素であるチロシナーゼに変異が生じると、皮膚、毛髪のメラニン色素の形成が異常となることが報告されている(非特許文献1参照)。
メラニン生合成におけるチロシナーゼの重要度の高さから、チロシナーゼは美白素材のターゲットとしても古くから注目されてきた。チロシナーゼはチロシンヒドロキシラーゼ活性、ドーパオキシダーゼ活性及びDHI活性を有し、チロシンを前駆体としたメラニン合成反応を触媒する。チロシナーゼ酵素活性はドーパオキシダーゼ活性を指標とすることができ、チロシナーゼ酵素活性阻害作用をもつメラニン産生抑制素材を評価する際にもその指標として用いられている(非特許文献2参照)。よってメラノサイト内ドーパオキシダーゼ活性を抑制することで、最終的な生合成産物であるメラニンの産出を抑制することができる。
従来から、チロシナーゼの活性を阻害してメラニン産生を抑制したり、産生したメラニンを減少させる物質の使用が検討され、アスコルビン酸、アルブチン、コウジ酸、グルタチオン等に当該作用があることが報告されている(例えば、非特許文献3参照)。
しかし、これらの物質には、メラニン産生抑制効果が十分でない等の問題がある場合もあり、未だ十分に満足できるものは得られていない。
Pigmentation after sunburn, spots and freckles generally result from increased melanin production by activation of pigment cells (melanocytes) in the skin due to irritation caused by ultraviolet exposure to the skin, hormonal abnormalities or genetic factors It is believed that. In vivo, pigment melanin is biosynthesized from tyrosine, a precursor, in melanosomes in pigment cells (melanocytes). It has been reported that when a mutation occurs in tyrosinase, which is an enzyme involved in melanin biosynthesis, the formation of melanin pigments in the skin and hair becomes abnormal (see Non-Patent Document 1).
Because of the high importance of tyrosinase in melanin biosynthesis, tyrosinase has long been attracting attention as a target for whitening materials. Tyrosinase has tyrosine hydroxylase activity, dopa oxidase activity, and DHI activity, and catalyzes a melanin synthesis reaction using tyrosine as a precursor. Tyrosinase enzyme activity can use dopa oxidase activity as an index, and is also used as an index when evaluating a melanin production-suppressing material having an inhibitory action on tyrosinase enzyme activity (see Non-Patent Document 2). Therefore, the production of melanin, which is the final biosynthetic product, can be suppressed by suppressing the melanocyte dopa oxidase activity.
Conventionally, the use of substances that inhibit the activity of tyrosinase to suppress melanin production or reduce the produced melanin has been studied, and it has been reported that ascorbic acid, arbutin, kojic acid, glutathione, etc. have this effect. (For example, see Non-Patent Document 3).
However, these substances sometimes have problems such as an insufficient melanin production inhibitory effect, and a substance that has not been fully satisfied has not yet been obtained.

King RA.Oetting WS.Hearing VJ.In Metabolic bases of inherited disease(Scriver CR.Beaudet AL.Sly WS.Valle D.,eds.),McGraw-Hill,New York,4353-4392,1995King RA. Oetting WS. Hearing VJ. In Metabolic bases of inherited disease (Scriver CR. Beaudet AL. Sly WS. Valle D., eds.), McGraw-Hill, New York, 4353-4392, 1995 Wrathall JR.et al.,JCB 1973 57:406-423Wrathall JR. et al., JCB 1973 57: 406-423 美白戦略(南江堂)IV.,美白剤の薬理と臨床,p95−115Whitening Strategy (Nanedo) IV., Pharmacology and Clinic of Whitening Agent, p95-115

本発明は、ドーパオキシダーゼ活性を効果的に抑制することができるドーパオキシダーゼ活性抑制剤を提供することを課題とする。また、本発明は、ドーパオキシダーゼ活性を抑制することでメラニンの産生を抑制する美白剤を提供することを課題とする。   This invention makes it a subject to provide the dopa oxidase activity inhibitor which can suppress dopa oxidase activity effectively. Moreover, this invention makes it a subject to provide the whitening agent which suppresses production of melanin by suppressing dopa oxidase activity.

本発明者等は上記課題に鑑み、鋭意検討を行った。その結果、ある種の植物の抽出物がドーパオキシダーゼ活性抑制作用を有することを見い出した。さらに、この抽出物を用いることで、優れたドーパオキシダーゼ活性抑制剤および美白剤を提供することができることを見い出した。本発明はこれらの知見に基づいて完成するに至ったものである。   In view of the above problems, the present inventors have conducted intensive studies. As a result, it was found that certain plant extracts have a dopa oxidase activity inhibitory action. Furthermore, it has been found that an excellent dopa oxidase activity inhibitor and whitening agent can be provided by using this extract. The present invention has been completed based on these findings.

本発明は、セイヨウトウキ(Angelica archangelica)、ハナミズキ(Benthamidia florida)、カンスイ(Euphorbia kansui Liou)、ヌルデ(Rhus chinensis Mill.)、オカゼリ(Cnidium monnieri(L.)Cuss.)、キンミズヒキ(Agrimonia pilosa Ledeb.)、ロウロ(Diuranthera minor(C.H.Wright)Hemsl.)及びセイヨウメギ(Berberis aristata)からなる群より選ばれる少なくとも1種の植物の抽出物を有効成分として含有する美白剤およびドーパオキシダーゼ活性抑制剤に関する。 The present invention includes the followings: Angelica archangelica , dogwood ( Benthamidia florida ), kansui ( Euphorbia kansui Liou), Nurde ( Rhus chinensis Mill.), Okazeli ( Cnidium monnieri (L.) Cuss.), And Agrimonia pilosa Ledeb. ), Rouro ( Diuranthera minor (CHWright) Hemsl.) And at least one plant extract selected from the group consisting of Berberis aristata as a whitening agent and a dopa oxidase activity inhibitor.

本発明において、「美白(作用)」とは、メラニン色素の生成を抑え、余分なメラニンのない本来の透明な肌色に戻すこと、または皮膚の黒化若しくはシミ・ソバカス等の色素沈着を防止、抑制することを意味する。   In the present invention, “whitening (action)” refers to suppressing the production of melanin pigments, returning to the original transparent skin color without excess melanin, or preventing pigmentation such as blackening of the skin or spots and freckles. Means to suppress.

本発明のドーパオキシダーゼ活性抑制剤は、ドーパオキシダーゼ活性を効果的に抑制することができる。また、本発明の美白剤は、ドーパオキシダーゼ活性を抑制することでメラニンの産生を抑制することができ、美白効果を有する。   The dopa oxidase activity inhibitor of the present invention can effectively suppress dopa oxidase activity. Moreover, the whitening agent of this invention can suppress the production of melanin by suppressing dopa oxidase activity, and has a whitening effect.

以下、本発明を詳細に説明する。
本発明のドーパオキシダーゼ活性抑制剤および美白剤は、セイヨウトウキ(Angelica archangelica)、ハナミズキ(Benthamidia florida)、カンスイ(Euphorbia kansui Liou)、ヌルデ(Rhus chinensis Mill.)、オカゼリ(Cnidium monnieri(L.)Cuss.)、キンミズヒキ(Agrimonia pilosa Ledeb.)、ロウロ(Diuranthera minor(C.H.Wright)Hemsl.)及びセイヨウメギ(Berberis aristata)からなる群より選ばれる少なくとも1種の植物の抽出物を有効成分として含有する。
前記植物の抽出物は、ドーパオキシダーゼ活性抑制効果を有する。そのため、前記植物の抽出物を含有することで本発明の美白剤は、皮膚におけるメラニンの産生を抑制することができ、美白効果を奏する。
Hereinafter, the present invention will be described in detail.
The dopa oxidase activity inhibitor and the whitening agent of the present invention include: Angelica archangelica , dogwood ( Benthamidia florida ), kansui ( Euphorbia kansui Liou), Nurde ( Rhus chinensis Mill.), Okaseri ( Cnidium monnieri (L.) Cuss .), An extract of at least one plant selected from the group consisting of Agrimonia pilosa Ledeb., Louro ( Diuranthera minor (CHWright) Hemsl.), And Berberis aristata .
The plant extract has an inhibitory effect on dopa oxidase activity. Therefore, the whitening agent of this invention can suppress the production of melanin in skin by containing the extract of the said plant, and there exists a whitening effect.

本発明におけるセイヨウトウキ(Angelica archangelica:ヨーロッパトウキともいう。)は、セリ科(Apiaceae)に属する植物である。 Angelica archangelica in the present invention (Angelica archangelica:. Also called Europe Angelica) is a plant belonging to the Umbelliferae (Apiaceae).

本発明におけるハナミズキ(Benthamidia florida)は、ミズキ科(Cornaceae)に属する植物である。 The dogwood ( Benthamidia florida ) in the present invention is a plant belonging to the family Cornaceae .

本発明におけるカンスイ(Euphorbia kansui Liou)は、トウダイグサ科(Euphorbiaceae)に属する植物である。 The kansui ( Euphorbia kansui Liou) in this invention is a plant which belongs to Euphorbiaceae .

本発明におけるヌルデ(Rhus chinensis Mill.)は、ウルシ科(Anacardiaceae)に属する植物である。 Nurde ( Rhus chinensis Mill.) In the present invention is a plant belonging to the family Uraceae ( Anacardiaceae ).

本発明におけるオカゼリ(Cnidium monnieri(L.)Cuss.)は、セリ科(Apiaceae)に属する植物である。別名、蛇床ともいう。 Ocaseri ( Cnidium monnieri (L.) Cuss.) In the present invention is a plant belonging to the family Apiaceae . Also called snake bed.

本発明におけるキンミズヒキ(Agrimonia pilosa Ledeb.)は、バラ科(Rosaceae)に属する植物である。別名、龍芽草ともいう。 In the present invention, Agrimonia pilosa Ledeb. Is a plant belonging to the family Rosaceae . Also known as Dragon Meadow.

本発明におけるロウロ(Diuranthera minor(C.H.Wright)Hemsl.)は、ユリ科(Liliaceae)に属する植物である。 In the present invention, Louro ( Diuranthera minor (CHWright) Hemsl.) Is a plant belonging to the family Liliaceae .

本発明におけるセイヨウメギ(Berberis aristata)は、メギ科(Berberidaceae)に属する植物である。 The barberry ( Berberis aristata ) in the present invention is a plant belonging to the Berberidaceae family.

本発明において、前記植物の全ての任意の部分が使用可能である。例えば、上記植物の全木、または任意の部位(根、根茎、幹、枝、茎、葉、樹皮、樹液、樹脂、花、果実、種子等)、およびそれらの組み合わせのいずれか1つまたは複数を使用することができる。   In the present invention, any arbitrary part of the plant can be used. For example, any one or more of the whole tree of the above plant, or any part (root, rhizome, stem, branch, stem, leaf, bark, sap, resin, flower, fruit, seed, etc.), and combinations thereof Can be used.

本発明において、セイヨウトウキ(Angelica archangelica)の抽出物を得るためには、前記植物の根を用いるのが好ましく、セイヨウトウキ(Angelica archangelica)を基原植物として得られた生薬(当帰(トウキ))を用いることもできる。 In the present invention, Angelica archangelica in order to obtain extracts (Angelica archangelica), it is preferable to use the roots of the plant were obtained Angelica archangelica a (Angelica archangelica) as MotoHara plant crude drug (angelica (Angelica) ) Can also be used.

本発明において、ハナミズキ(Benthamidia florida)の抽出物を得るためには、前記植物の樹皮を用いるのが好ましい。 In the present invention, in order to obtain an extract of dogwood ( Benthamidia florida ), it is preferable to use the bark of the plant.

本発明において、カンスイ(Euphorbia kansui Liou)の抽出物を得るためには、前記植物の種子を用いるのが好ましく、カンスイ(Euphorbia kansui Liou)を基原植物として得られた生薬(甘遂(カンツイ))を用いることもできる。 In the present invention, in order to obtain an extract of kansui ( Euphorbia kansui Liou), it is preferable to use the seeds of the plant, and a herbal medicine (kantsui) obtained using kansui (Euphorbia kansui Liou) as a base plant. ) Can also be used.

本発明において、ヌルデ(Rhus chinensis Mill.)の抽出物を得るためには、前記植物の虫嚢体を用いるのが好ましく、ヌルデ(Rhus chinensis Mill.)を基原植物として得られた生薬(五倍子(ゴバイシ))を用いることもできる。 In the present invention, in order to obtain an extract of Nurde ( Rhus chinensis Mill.), It is preferable to use the insect sac body of the above plant, and a crude drug (pentuplet) obtained using Nurde ( Rhus chinensis Mill.) As a basic plant. (Gobishi)) can also be used.

本発明において、オカゼリ(Cnidium monnieri(L.)Cuss.)の抽出物を得るためには、前記植物の果実を用いるのが好ましく、オカゼリ(Cnidium monnieri(L.)Cuss.)を基原植物として得られた生薬(蛇床子(ジャショウシ))を用いることもできる。 In the present invention, in order to obtain an extract of Okazeri (Cnidium monnieri (L.) Cuss. ) , It is preferable to use the fruit of the plant, Okazeri the (Cnidium monnieri (L.) Cuss. ) As MotoHara plant The obtained crude drug (snake bed (jashoushi)) can also be used.

本発明において、キンミズヒキ(Agrimonia pilosa Ledeb.)の抽出物を得るためには、前記植物の全草を用いるのが好ましく、キンミズヒキ(Agrimonia pilosa Ledeb.)を基原植物として得られた生薬(仙鶴草(センカクソウ))を用いることもできる。 In the present invention, in order to obtain an extract of Agrimonia pilosa Ledeb., It is preferable to use the whole plant, and a crude drug obtained from Agrimonia pilosa Ledeb. (Senkaxou)) can also be used.

本発明において、ロウロ(Diuranthera minor(C.H.Wright)Hemsl.)の抽出物を得るためには、前記植物の根を用いるのが好ましく、ロウロ(Diuranthera minor(C.H.Wright)Hemsl.)を基原植物として得られた生薬(漏蘆(ロウロ))を用いることもできる。 In the present invention, in order to obtain an extract of Louro ( Diuranthera minor (CHWright) Hemsl.), It is preferable to use the roots of the plant, and Louro ( Diuranthera minor (CHWright) Hemsl.) Can be obtained as a base plant. Herbal medicine (leakage) can also be used.

本発明において、セイヨウメギ(Berberis aristata)の抽出物を得るためには、前記植物の樹皮を用いるのが好ましい。 In the present invention, the bark of the plant is preferably used in order to obtain an extract of berberis aristata .

本発明において用いる、前記植物の抽出物は、適当な溶媒を用いた常法の抽出方法によって調製することができる。   The plant extract used in the present invention can be prepared by a conventional extraction method using an appropriate solvent.

本発明において、前記植物の抽出物の調製に、上記植物をそのまま、又は乾燥粉砕して用いることもできるが、その水蒸気蒸留物又は圧搾物を用いることもでき、これらは精油等、より精製したものを用いることもでき、また市販品を利用することもできる。上記植物又はその水蒸気蒸留物若しくは圧搾物は、いずれかを単独で、又は2種以上を組み合わせて使用してもよい。   In the present invention, the above plant can be used as it is or after being dried and pulverized for the preparation of the plant extract, but its steam distillate or compressed product can also be used. A thing can also be used and a commercial item can also be utilized. You may use the said plant or its steam distillate or pressing material individually or in combination of 2 or more types.

抽出に用いる溶媒としては、通常植物成分の抽出に用いられるもの、例えば水、石油エーテル、n−ヘキサン、トルエン、クロロホルム、エーテル、酢酸エチル、アセトン、メタノール、エタノール、プロパノール、ブタノール、エチレングリコール、プロピレングリコール、ブチレングリコール等が挙げられ、特に水、エタノール、プロピレングリコール、ブチレングリコールが好ましい。これらは単独で又は2種以上を組み合わせて使用できる。また抽出条件も通常の条件を適用でき、例えば上記植物を5〜80℃で2時間〜60日間浸漬又は加熱還流すればよい。上記植物の抽出物は、そのまま使用できるが、さらに適当な分離手段、例えばゲル濾過、クロマトグラフィー、精密蒸留、活性炭処理等により活性の高い画分を分画して用いることもできる。   Solvents used for extraction are those usually used for extraction of plant components, such as water, petroleum ether, n-hexane, toluene, chloroform, ether, ethyl acetate, acetone, methanol, ethanol, propanol, butanol, ethylene glycol, propylene. Examples include glycol, butylene glycol, and water, ethanol, propylene glycol, and butylene glycol are particularly preferable. These can be used alone or in combination of two or more. Moreover, normal conditions can be applied as extraction conditions. For example, the above-described plant may be immersed or heated to reflux at 5 to 80 ° C. for 2 hours to 60 days. The plant extract can be used as it is, but a fraction having high activity can be fractionated by an appropriate separation means such as gel filtration, chromatography, precision distillation, activated carbon treatment and the like.

本発明において、前記植物の抽出物はそのまま用いてもよい。または、当該抽出物を希釈、濃縮または凍結乾燥した後、粉末またはペースト状に調製して用いることもできる。   In the present invention, the plant extract may be used as it is. Alternatively, the extract can be diluted, concentrated, or lyophilized and then prepared into a powder or paste.

前記植物の抽出物は、ドーパオキシダーゼ活性抑制作用を有する。これら植物の抽出物を有効成分として含有させることで、本発明のドーパオキシダーゼ活性抑制剤および美白剤が得られる。
本発明において、前記植物の抽出物はそのままドーパオキシダーゼ活性抑制剤および美白剤として用いてもよい。または、上記抽出物に、例えば酸化チタン、炭酸カルシウム、蒸留水、乳糖、デンプン等の適当な液体または固体の賦形剤または増量剤を加えて用いてもよい。この場合、これら植物の抽出物の量は特に制限されないが、前記抽出物が固形分換算で0.00001〜5重量%含まれるのが好ましく、0.0001〜0.5重量%含まれるのが特に好ましい。
The plant extract has an inhibitory action on dopa oxidase activity. By containing these plant extracts as active ingredients, the dopa oxidase activity inhibitor and the whitening agent of the present invention can be obtained.
In the present invention, the plant extract may be used as it is as a dopa oxidase activity inhibitor and a whitening agent. Alternatively, an appropriate liquid or solid excipient or extender such as titanium oxide, calcium carbonate, distilled water, lactose, starch or the like may be added to the above extract. In this case, the amount of the plant extract is not particularly limited, but the extract is preferably contained in an amount of 0.00001 to 5% by weight, and 0.0001 to 0.5% by weight in terms of solid content. Particularly preferred.

以下、本発明を実施例に基づきさらに詳細に説明するが、本発明はこれに限定されるものではない。   EXAMPLES Hereinafter, although this invention is demonstrated further in detail based on an Example, this invention is not limited to this.

(製造例1)セイヨウトウキの抽出物の調製
セイヨウトウキを基原植物とする生薬トウキ(当帰)(新和物産社製)40gを細切し、50%エタノール400mLを加え、室温で17日間抽出後、濾過して粗抽出液を得た(収量283mL、蒸発残分2.34w/v%)。粗抽出液を蒸発残分1.0w/v%となるよう希釈し、セイヨウトウキ抽出物を調製した。
(Production Example 1) Preparation of an extract of pearl cherries 40 g of crude herb (Toki) (manufactured by Shinwa Bussan Co., Ltd.) using pearl oysters as the base plant, add 400 mL of 50% ethanol, and add at room temperature for 17 days After extraction, filtration was performed to obtain a crude extract (yield 283 mL, evaporation residue 2.34 w / v%). The crude extract was diluted to an evaporation residue of 1.0 w / v% to prepare a sugar beet extract.

(製造例2)ハナミズキの抽出物の調製
ハナミズキの樹皮(American botanicals社製)40gを細切し、50%エタノール400mLを加え、室温で22日間抽出後、濾過して粗抽出液を得た(収量305mL、蒸発残分1.08w/v%)。粗抽出液を蒸発残分1.0w/v%となるよう希釈し、ハナミズキ抽出物を調製した。
(Production Example 2) Preparation of Dogwood Extract 40 g of dogwood bark (American botanicals) was chopped, added with 400 mL of 50% ethanol, extracted at room temperature for 22 days, and then filtered to obtain a crude extract ( Yield 305 mL, evaporation residue 1.08 w / v%). The crude extract was diluted to an evaporation residue of 1.0 w / v% to prepare a dogwood extract.

(製造例3)カンスイの抽出物の調製
カンスイを基原植物とする生薬カンツイ(甘遂)(新和物産社製)100gを細切し、50%エタノール500mLを加え、室温で3日間抽出後、濾過して粗抽出液を得た(収量224mL、蒸発残分1.56w/v%)。粗抽出液を蒸発残分1.0w/v%となるよう希釈し、カンスイ抽出物を調製した。
(Production Example 3) Preparation of Kansui extract 100 g of herb medicine Kantsui (Kansai) (manufactured by Shinwa Bussan Co., Ltd.) using Kansui as a base plant, add 500 mL of 50% ethanol, and extract at room temperature for 3 days The crude extract was obtained by filtration (yield 224 mL, evaporation residue 1.56 w / v%). The crude extract was diluted to an evaporation residue of 1.0 w / v% to prepare a Kansui extract.

(製造例4)ヌルデの抽出物の調製
ヌルデを基原植物とする生薬ゴバイシ(五倍子)(新和物産社製)100gを細切し、50%エタノール500mLを加え、室温で30日間抽出後、濾過して粗抽出液を得た(収量335mL、蒸発残分13.59w/v%)。粗抽出液を蒸発残分1.0w/v%となるよう希釈し、ヌルデ抽出物を調製した。
(Production Example 4) Preparation of Nurde extract 100 g of crude herb gobishi (penta) (manufactured by Shinwa Bussan Co., Ltd.) with Nurde as the base plant, added with 500 mL of 50% ethanol, extracted at room temperature for 30 days, Filtration gave a crude extract (yield 335 mL, evaporation residue 13.59 w / v%). The crude extract was diluted to an evaporation residue of 1.0 w / v% to prepare a null de extract.

(製造例5)オカゼリの抽出物の調製
オカゼリを基原植物とする生薬ジャショウシ(蛇床子)(新和物産社製)100gを細切し、50%エタノール500mLを加え、室温で2日間抽出後、濾過して粗抽出液を得た(収量117mL、蒸発残分1.54w/v%)。粗抽出液を蒸発残分1.0w/v%となるよう希釈し、オカゼリ抽出物を調製した。
(Manufacture example 5) Preparation of an extract of casserole 100 g of a crude drug Jasho beef (snake bed) (manufactured by Shinwa Bussan Co., Ltd.) using okaseri as a base plant, add 500 mL of 50% ethanol, and extract at room temperature for 2 days The crude extract was obtained by filtration (yield 117 mL, evaporation residue 1.54 w / v%). The crude extract was diluted to an evaporation residue of 1.0 w / v% to prepare an okaseri extract.

(製造例6)キンミズヒキの抽出物の調製
キンミズヒキを基原植物とする生薬センカクソウ(仙鶴草)(新和物産社製)100gを細切し、50%エタノール500mLを加え、室温で4日間抽出後、濾過して粗抽出液を得た(収量275mL、蒸発残分1.73w/v%)。粗抽出液を蒸発残分1.0w/v%となるよう希釈し、キンミズヒキ抽出物を調製した。
(Manufacture example 6) Preparation of an extract of kingworms 100 g of raw herb senkaxou (Sengakuso) (made by Shinwa Bussan), which uses oxworms as a base plant, was cut into 500 mL of 50% ethanol, and extracted at room temperature for 4 days. The crude extract was obtained by filtration (yield 275 mL, evaporation residue 1.73 w / v%). The crude extract was diluted to an evaporation residue of 1.0 w / v% to prepare a Kimizumi extract.

(製造例7)ロウロの抽出物の調製
ロウロを基原植物とする生薬ロウロ(漏蘆)(新和物産社製)50gを細切し、50%エタノール500mLを加え、室温で2日間抽出後、濾過して粗抽出液を得た(収量298mL、蒸発残分2.01w/v%)。粗抽出液を蒸発残分1.0w/v%となるよう希釈し、ロウロ抽出物を調製した。
(Production Example 7) Preparation of extract of Louro 50 g of crude oil Loro (leak) (manufactured by Shinwa Bussan Co., Ltd.) using Louro as a base plant, added with 500 mL of 50% ethanol, and extracted at room temperature for 2 days The crude extract was obtained by filtration (yield 298 mL, evaporation residue 2.01 w / v%). The crude extract was diluted to an evaporation residue of 1.0 w / v% to prepare a rouro extract.

(製造例8)セイヨウメギの抽出物の調製
セイヨウメギの樹皮(商品名:BARBERRYS,新和物産社製)50gを細切し、50%エタノール500mLを加え、室温で19日間抽出後、濾過して粗抽出液を得た(収量323mL、蒸発残分0.25w/v%)。粗抽出液を蒸発残分1.0w/v%となるよう濃縮し、セイヨウメギ抽出物を調製した。
(Production Example 8) Preparation of an extract of cedar bark 50 g of bark of pearl barley (trade name: BARBERRYS, manufactured by Shinwa Bussan Co., Ltd.) was added, 500 mL of 50% ethanol was added, extracted at room temperature for 19 days, filtered and coarsely An extract was obtained (yield 323 mL, evaporation residue 0.25 w / v%). The crude extract was concentrated to an evaporation residue of 1.0 w / v% to prepare a cedar extract.

(実施例1)ドーパオキシダーゼ活性の測定
96穴プレートにヒト新生児***由来のメラノサイト100μlを1×10cell/wellの細胞密度となるように各穴に播種した。培地はMedium254にPMAを除くHMGS(Human Melanocyte Growth Supplement)(いずれもCascade Biologics社製)を添加したものを用いた。
24時間の培養後、メラノサイト活性化因子エンドセリン−1(ET−1)、幹細胞増殖因子(SCF)、αメラノサイト刺激ホルモン(α−MSH)、ヒスタミンおよびプロスタグランジンE2(PGE2)を、それぞれ培地中終濃度で10×10-7mol/m3になるように添加した。
(Example 1) were seeded into each well as a measure 96 well plate dopa oxidase activity becomes a cell density of melanocytes 100μl of 1 × 10 4 cell / well derived from human neonatal foreskin. The medium used was medium 254 supplemented with HMGS (Human Melanocyte Growth Supplement) excluding PMA (both manufactured by Cascade Biologics).
After culturing for 24 hours, melanocyte activator endothelin-1 (ET-1), stem cell growth factor (SCF), α melanocyte stimulating hormone (α-MSH), histamine and prostaglandin E 2 (PGE 2 ), respectively, The final concentration in the medium was 10 × 10 −7 mol / m 3 .

また、前記製造例1〜製造例8で調製した植物の抽出物を0.10%となるように添加した。最終的に培地量は200μl/wellで、37℃、5%CO2の条件下で3日間培養を行った。 Moreover, the plant extract prepared in Production Example 1 to Production Example 8 was added to 0.10%. Finally, the amount of the medium was 200 μl / well, and the cells were cultured for 3 days under conditions of 37 ° C. and 5% CO 2 .

なお、培地には、以下の添加物も添加されている。
bFGF(塩基性線維芽細胞成長因子) 3ng/ml
BPE(ウシ脳下垂体抽出液) 0.2体積%
FBS(ウシ胎児血清) 0.5体積%
ハイドロコーチゾン 5×10-4mol/m3
インスリン 5μg/ml
トランスフェリン 5μg/ml
ヘパリン 5μg/ml
In addition, the following additives are also added to the medium.
bFGF (basic fibroblast growth factor) 3 ng / ml
BPE (bovine pituitary extract) 0.2% by volume
FBS (fetal bovine serum) 0.5% by volume
Hydrocortisone 5 × 10 -4 mol / m 3
Insulin 5 μg / ml
Transferrin 5 μg / ml
Heparin 5μg / ml

培養終了後、各ウェルにアラマーブルー(Alamar Blue、商品名、インビトロジェン社製)試薬20μlを添加し、2〜3時間培養後、培地の蛍光強度(励起波長;544nm、蛍光波長;590nm)を測定して細胞増殖活性を測定した。その結果を表1に示す。
細胞増殖活性を測定したメラノサイトをCa2+およびMg2+を除去したPhosphate−buffered saline(PBS)で洗浄し、抽出バッファー(0.1M Tris−HCL(pH7.2)、1%Nonidet P−40、0.01%SDS、100μM PMSF(フェニルメチルスルホニルフルオライド)、1μg/mlアプロチニン)を20μl/well、Assay buffer(4%ジメチルホルムアミドを含有する100mM Sodium phosphate−buffered(pH7.1))を20μL/well添加し、4℃、3時間で細胞を可溶化し、ドーパオキシターゼ活性の測定を行った。ドーパオキシターゼ活性測定は、MBTH法(例えば、Winder A.J.,Harris H.,Eur.J.Biochem.,198,317-326,1991参照)を参考に、以下のように行った。
After completion of the culture, 20 μl of Alamar Blue (Alamar Blue, trade name, manufactured by Invitrogen) reagent is added to each well, and after culturing for 2-3 hours, the fluorescence intensity of the medium (excitation wavelength: 544 nm, fluorescence wavelength: 590 nm) is measured. The cell proliferation activity was measured. The results are shown in Table 1.
Melanocytes whose cell proliferation activity was measured were washed with Phosphate-buffered saline (PBS) from which Ca 2+ and Mg 2+ were removed, and extracted buffer (0.1 M Tris-HCL (pH 7.2), 1% Nonidet P-40 0.01% SDS, 100 μM PMSF (phenylmethylsulfonyl fluoride), 1 μg / ml aprotinin) 20 μl / well, Assay buffer (100 mM sodium phosphate-buffered (pH 7.1) containing 4% dimethylformamide) 20 μL / Well was added, the cells were solubilized at 4 ° C. for 3 hours, and the dopa oxidase activity was measured. The dopa oxidase activity was measured as follows with reference to the MBTH method (see, for example, Winder AJ, Harris H., Eur. J. Biochem., 198, 317-326, 1991).

可溶化した細胞溶液の各wellに、Assay bufferを80μL/well、20.7mM MBTH(3−メチル−2−ベンゾチアゾリノン ヒドラゾン)溶液を60μL、基質として5mM L−ドーパ(L−ジヒドロキシフェニルアラニン)溶液を40μl、それぞれ加え、37℃で30〜60分反応させた後、その呈色反応を490nmの吸光度で測定した。
その結果を表1に示す。なお、表1の細胞増殖活性の値は、各種植物の抽出物を添加しなかった場合の蛍光強度に対する相対値で示している。また、ドーパオキシダーゼ活性の値は、各種植物の抽出物を添加しなかった場合の吸光度に対する相対値で示している。
In each well of the solubilized cell solution, Assay buffer is 80 μL / well, 20.7 mM MBTH (3-methyl-2-benzothiazolinone hydrazone) solution is 60 μL, and 5 mM L-dopa (L-dihydroxyphenylalanine) is used as a substrate. After adding 40 μl of each solution and reacting at 37 ° C. for 30 to 60 minutes, the color reaction was measured by absorbance at 490 nm.
The results are shown in Table 1. In addition, the value of the cell proliferation activity of Table 1 is shown by the relative value with respect to the fluorescence intensity at the time of not adding the extract of various plants. Moreover, the value of the dopa oxidase activity is shown by the relative value with respect to the light absorbency when the extract of various plants is not added.

Figure 2010195731
Figure 2010195731

表1に示したとおり、前記製造例1〜製造例8で調製した抽出物は、ドーパオキシダーゼ活性を抑制することが認められた。前述のように、ドーパオキシダーゼ活性はメラニン生合成に関与するチロシナーゼの酵素活性の指標として用いられている。したがって、表1の結果から、本発明の前記製造例1〜製造例8で調製した抽出物は、ドーパオキシダーゼ活性を抑制することでメラニン産生を抑制し、その結果、美白作用を有することがわかる。
また、前記製造例1〜製造例8で調製した抽出物のうち、セイヨウトウキおよびヌルデについては、わずかに細胞増殖活性が低下していた。一方、それ以外の抽出物については、細胞増殖活性に上昇がみられた。したがって、本発明の前記植物抽出物は、細胞増殖活性を大きく低下させる作用(すなわち、細胞増殖能を大幅に低下させる作用)がないことがわかった。
さらに、実施例1で得られた結果との比較から、本発明の前記植物抽出物は細胞増殖活性をほとんど抑制することなく、ドーパオキシダーゼ活性を抑制できることがわかった。
As shown in Table 1, it was confirmed that the extracts prepared in Production Examples 1 to 8 inhibit dopa oxidase activity. As described above, dopa oxidase activity is used as an indicator of enzyme activity of tyrosinase involved in melanin biosynthesis. Therefore, from the results of Table 1, it can be seen that the extracts prepared in Production Examples 1 to 8 of the present invention inhibit melanin production by inhibiting dopa oxidase activity and, as a result, have a whitening effect. .
In addition, among the extracts prepared in Production Examples 1 to 8, cell proliferation activity was slightly decreased with respect to the sugar beet and nullde. On the other hand, for the other extracts, there was an increase in cell proliferation activity. Therefore, it was found that the plant extract of the present invention does not have an effect of greatly reducing cell proliferation activity (that is, an effect of greatly reducing cell proliferation ability).
Furthermore, from the comparison with the results obtained in Example 1, it was found that the plant extract of the present invention can suppress the dopa oxidase activity without substantially suppressing the cell growth activity.

Claims (2)

セイヨウトウキ(Angelica archangelica)、ハナミズキ(Benthamidia florida)、カンスイ(Euphorbia kansui Liou)、ヌルデ(Rhus chinensis Mill.)、オカゼリ(Cnidium monnieri(L.)Cuss.)、キンミズヒキ(Agrimonia pilosa Ledeb.)、ロウロ(Diuranthera minor(C.H.Wright)Hemsl.)及びセイヨウメギ(Berberis aristata)からなる群より選ばれる少なくとも1種の植物の抽出物を有効成分として含有するドーパオキシダーゼ活性抑制剤。 Angelica archangelica , dogwood ( Benthamidia florida ), kansui ( Euphorbia kansui Liou), Nurde ( Rhus chinensis Mill.), Okazeri ( Cnidium monnieri (L.) Cuss.), Ginseng ( Agrimonia pilosa Ledeb. A dopa oxidase activity inhibitor comprising as an active ingredient at least one plant extract selected from the group consisting of Diuranthera minor (CHWright) Hemsl.) And Berberis aristata . セイヨウトウキ(Angelica archangelica)、ハナミズキ(Benthamidia florida)、カンスイ(Euphorbia kansui Liou)、ヌルデ(Rhus chinensis Mill.)、オカゼリ(Cnidium monnieri(L.)Cuss.)、キンミズヒキ(Agrimonia pilosa Ledeb.)、ロウロ(Diuranthera minor(C.H.Wright)Hemsl.)及びセイヨウメギ(Berberis aristata)からなる群より選ばれる少なくとも1種の植物の抽出物を有効成分として含有する美白剤。 Angelica archangelica (Angelica archangelica), dogwood (Benthamidia florida), brine (Euphorbia kansui Liou), Rhus chinensis (Rhus chinensis Mill.), Okazeri (Cnidium monnieri (L.) Cuss. ), Agrimony (Agrimonia pilosa Ledeb.), Rouro ( A whitening agent containing at least one plant extract selected from the group consisting of Diuranthera minor (CHWright) Hemsl.) And Berberis aristata as an active ingredient.
JP2009044191A 2009-02-26 2009-02-26 Dopa oxidase activity inhibitor and beautifying agent Withdrawn JP2010195731A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009044191A JP2010195731A (en) 2009-02-26 2009-02-26 Dopa oxidase activity inhibitor and beautifying agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009044191A JP2010195731A (en) 2009-02-26 2009-02-26 Dopa oxidase activity inhibitor and beautifying agent

Publications (1)

Publication Number Publication Date
JP2010195731A true JP2010195731A (en) 2010-09-09

Family

ID=42820851

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009044191A Withdrawn JP2010195731A (en) 2009-02-26 2009-02-26 Dopa oxidase activity inhibitor and beautifying agent

Country Status (1)

Country Link
JP (1) JP2010195731A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9339454B2 (en) 2011-01-21 2016-05-17 Kao Corporation Skin whitening agent
US9486488B2 (en) 2011-09-01 2016-11-08 Kao Corporation Skin-lightening agent
WO2021038904A1 (en) * 2019-08-30 2021-03-04 株式会社紀文食品 Manufacturing method for composition with reduced urushiol content, composition manufactured using said manufacturing method, obesity prevention agent, fat accumulation suppression agent, and serum leptin quantity increase suppression agent
JP2021080212A (en) * 2019-11-20 2021-05-27 日本メナード化粧品株式会社 Cell proliferation promoter, mmp-2 inhibitor, topical skin preparation, pharmaceutical and internal preparation

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9339454B2 (en) 2011-01-21 2016-05-17 Kao Corporation Skin whitening agent
US9486488B2 (en) 2011-09-01 2016-11-08 Kao Corporation Skin-lightening agent
WO2021038904A1 (en) * 2019-08-30 2021-03-04 株式会社紀文食品 Manufacturing method for composition with reduced urushiol content, composition manufactured using said manufacturing method, obesity prevention agent, fat accumulation suppression agent, and serum leptin quantity increase suppression agent
JP2021038194A (en) * 2019-08-30 2021-03-11 株式会社紀文食品 Manufacturing method for composition with reduced urushiol content, composition manufactured using that manufacturing method, obesity prevention agent, fat accumulation suppression agent, and blood leptin quantity increase suppression agent
JP2021080212A (en) * 2019-11-20 2021-05-27 日本メナード化粧品株式会社 Cell proliferation promoter, mmp-2 inhibitor, topical skin preparation, pharmaceutical and internal preparation

Similar Documents

Publication Publication Date Title
Bose et al. Studies on secondary metabolite profiling, anti-inflammatory potential, in vitro photoprotective and skin-aging related enzyme inhibitory activities of Malaxis acuminata, a threatened orchid of nutraceutical importance
Chan et al. Inhibitory effects of Sargassum polycystum on tyrosinase activity and melanin formation in B16F10 murine melanoma cells
US20110117038A1 (en) Dopa Oxidase Inhibitor, Skin-Lightening Agent and External Preparation for Skin
Arung et al. Structure–activity relationship of prenyl‐substituted polyphenols from Artocarpus heterophyllus as inhibitors of melanin biosynthesis in cultured melanoma cells
US6521267B1 (en) Tyrosinase inhibitors from plants
KR20110054022A (en) Skin-whitening agent, anti-aging agent, and skin-care cosmetic agent
JP5226982B2 (en) A topical skin preparation containing an extract of buckwheat
KR101824770B1 (en) Anti-wrinkle cosmetic composition comprising essentially Polygonum multiflorum adventitious extract
JP2010195731A (en) Dopa oxidase activity inhibitor and beautifying agent
Hsu et al. Hypoglycemic activity of Chenopodium formosanum Koidz. components using a glucose uptake assay with 3T3-L1 adipocytes
JP2010195730A (en) Dopa oxidase activity promoter and melanin production promoter
Chaudhary et al. Investigation on protective effect of Terminalia bellirica (Roxb.) against drugs induced cardiotoxicity in wistar albino rats
Bhatnagar et al. Antioxidant activity of fruit pulp powder of Cassia fistula
Varadarajan et al. Assessing the in vitro antioxidant and anti-inflammatory activity of Moringa oleifera crude extract
Hassan et al. Antioxidant and tyrosinase inhibition activities of Eurycoma longifolia and Swietenia macrophylla
JP2010195732A (en) Dopa oxidase activity inhibitor, beautifying agent and skin care preparation for external use
US8673371B2 (en) Composition for treating vitiligo or canities comprising extract from sophora japonica as active ingredient
KR101903732B1 (en) Composition for whitening comprising an ethyl acetate fraction of Agastache rugosa Fisch. and C.A.Mey.Kuntze or an active compound isolated from the plant
KR101749549B1 (en) Skin-whitening composition comprising extract of Eisenia bicyclis
KR20070005049A (en) The leaf of extracts sasa quelpaertensis that having bleaching activity
JP2010159221A (en) Whitening agent, dopa oxidase activity inhibitor, cell-proliferative activity inhibitor, cosmetic composition and external composition for skin
KR100899847B1 (en) Cosmetic compositions for skin-whitening
KR101449559B1 (en) Plant extract from saxifragaceae plants having skin whitening effect and skin whitening cosmetic composition containing it as active ingredient
WO2018236304A2 (en) A plant based raw material effective against skin blemishes and a method for its production
Jiang et al. The Ethnopharmacological, Phytochemical and Pharmacological Review of Euryale ferox, a Medicine Food Homology Species

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111206

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20130308

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130315